Gastrointestinal Stromal Tumors

The literature grounding supports a genetic basis for many cases, with genomic alterations in KIT, PDGFRA, SDH, and BRAF implicated in oncogenesis. Primary KIT mutations are common in treatment-naive disease, and secondary KIT resistance mutations can emerge after therapy.

GIST biology is closely linked to KIT signaling, with both interstitial cells of Cajal lineage and GIST cells relying on this pathway. KIT mutations and overexpression drive tumor growth, and other oncogenic alterations such as PDGFRA, SDH, and BRAF mutations also contribute to disease development and clinical behavior.

The supplied grounding supports molecular features rather than clinical risk factors. KIT exon 11 deletions or exon 9 duplications are associated with worse prognosis, while KIT exon 11 substitutions and duplications are associated with better clinical outcome.

Treatment is centered on targeted therapy with imatinib mesylate for actionable KIT-mutant disease. The grounding also supports molecularly guided use of other targeted agents, including sunitinib and avapritinib for PDGFRA-mutant tumors, and tissue diagnosis is emphasized when lesions are suspicious for GIST and large enough or otherwise high risk.